Boston’s Brigham and Women’s Hospital (BWH) is an international leader in many areas of medicine and is a teaching hospital for Harvard Medical School. BWH has a well-developed lung transplant program and with the investment in the Ex Vivo Lung Perfusion (EVLP) technology and the XPS™ BWH will get the opportunity to increase the lung transplant program and support more patients.
XPS™ is the only CE-marked and FDA approved (Humanitarian Device Exemptions approval) integrated system on the market today which gives the user the flexibility to perform evaluation of lungs before transplantation through a standardized and simplified procedure. Use of XPS™ has shown good clinical results at 18 clinics in the US, many of which are national leaders in their field. Six XPS™ contracts have now been signed by European clinics, giving them access to the XPS™ system for lung transplantation, and the company notes continuing high interest for the XPS™ in the US and in Europe.
“We are delighted and proud that EVLP with XPS™ and STEEN Solution™ will be used for evaluating lungs for transplantation at the very well reputed Brigham and Women’s Hospital in Boston. This is one of only two hospitals performing lung transplantation in all of the states in the North-East (New England) of the USA. The company sees a continued high interest from American and European clinics to set up XVIVOs XPS ™ system to facilitate lung evaluation with the aim of using more of the donated lungs”, says Magnus Nilsson, CEO of XVIVO Perfusion.
April 15, 2016
Gothenburg
XVIVO Perfusion AB (publ)